<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02454140</url>
  </required_header>
  <id_info>
    <org_study_id>140103</org_study_id>
    <nct_id>NCT02454140</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiotherapy Dose Escalation in Pancreatic Cancer</brief_title>
  <acronym>SBRT</acronym>
  <official_title>Phase I Trial of Adaptive Stereotactic Body Radiotherapy (SBRT) Dose Escalation in Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the maximum tolerated dose (MTD) of five fraction stereotactic
      radiotherapy (SBRT) in pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is designed to find the maximum tolerated dose of radiation under a fixed
      5-fraction SBRT regimen escalating the dose from 40 Gy in 5 fractions, to 60 Gy in 5
      fractions, at 5 Gy intervals.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>From date of randomization to observed DLT in 20% of patients assessed up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Tumor Progression</measure>
    <time_frame>From date of randomization until local disease progression defined as a ≥20% increase in size on CT compared with CT prior to SBRT assessed over 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Metastatic Progression Rate</measure>
    <time_frame>From date of randomization until the appearance of new lesions or a ≥20% increase in size on CT of the previously noted metastatic lesions assessed over 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of diagnosis and SBRT to date of death assessed over 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT 40 Gy in 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT 45 Gy in 5 fractions (starting dose level)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT 50 Gy in 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT 55 Gy in 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT 60 Gy in 5 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Fixed five-fraction stereotactic radiotherapy</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis: Histologically-proven invasive adenocarcinoma of the pancreas.

          -  Disease Status: Medically unresectable (any stage), or locally advanced (stage III).

          -  Tumor Location: Primary tumor may be located anywhere in the pancreas.

          -  Treatment eligibility: The patient must be able to have fiducial markers implanted
             into the pancreatic tumor, and receive radiation regimen as specified in the protocol.

          -  Performance Level: Karnofsky Performance Status ≥ 60

          -  Adequate Renal Function Defined As: Serum creatinine ≤ 1.5 x upper limit of normal

          -  Informed Consent: All subjects must sign a written informed consent.

        Exclusion Criteria:

          -  Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entered on
             this study due to risks of fetal and teratogenic adverse events. (Note: Serum
             Pregnancy tests must be obtained in women of child bearing potential). Sexually active
             females may not participate unless they have agreed to use an effective contraceptive
             method (such as abstinence, diaphragm, condom, or intrauterine device) to prevent
             pregnancy for the duration of the study.

          -  Life expectancy &lt; 6 months

          -  The patient cannot have had prior radiation therapy to the thorax or upper abdomen.

          -  Incarcerated individuals

          -  Subjects unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D Murphy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>N. Rae Hintlian</last_name>
    <phone>(858) 822-5363</phone>
    <email>nrhintlian@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meaghan Stirn</last_name>
    <phone>(858) 822-5677</phone>
    <email>mstirn@ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>May 21, 2015</last_update_submitted>
  <last_update_submitted_qc>May 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>James D. Murphy, MD, MS</investigator_full_name>
    <investigator_title>Assistant Clinical Professor, Radiation Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

